Source comparison
The Naming Origin — Research Codes vs Generic Assignments
Pharmaceutical nomenclature operates on two parallel tracks. During early-stage development, compounds get internal alphanumeric codes from the sponsoring company. These codes have no pharmacological meaning but serve as shorthand for researchers tracking mult
This comparison does not assign a generated winner or score.
- Pharmaceutical nomenclature operates on two parallel tracks. During early-stage development, compounds get internal alphanumeric codes from the sponsoring company. These codes have no pharmacological meaning but serve as shorthand for researchers tracking multiple candidates through pre-clinical and Phase 1/2 trials. MK-677 was one of several growth hormone secretagogues Merck evaluated in the mid-1990s as a potential oral alternative to injectable recombinant GH. The 'MK' prefix denotes Merck's internal catalogue; the number is sequential.
- Once a compound advances far enough to warrant broader regulatory and scientific recognition, the World Health Organisation assigns an International Nonproprietary Name (INN). A standardised generic name that describes the molecule's structure or function. Ibutamoren was assigned as the INN in 1995, derived from the chemical class (secretagogue mimetics ending in '-morelin' or '-moren'). At that point, technically, all formal publications should have switched to 'ibutamoren'. But early Phase 2 data had already been published under MK-677, and that label stuck in research communities.
- What this means practically: if you're cross-referencing clinical trials, you'll find studies listed under both names. Sometimes in the same database. ClinicalTrials.gov entries from 1998–2008 predominantly use MK-677; publications after 2010 trend toward ibutamoren. The chemical structure hasn't changed. The pharmacokinetics haven't changed. It's purely a documentation artifact that both names remain in active use across supplier catalogues and research protocols.